Thrombin-cofactor interactions: Structural insights into regulatory mechanisms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 8, 2006, Pages 1738-1745

  Adams, Ty E ^a   Huntington, James A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cofactor; Hemostasis; Regulation; Specificity; Thrombin

Indexed keywords

FIBRIN; GLYCOPROTEIN IB ALPHA; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN COFACTOR; SODIUM ION; THROMBIN; THROMBOMODULIN; BLOOD CLOTTING FACTOR; SODIUM; THROMBIN RECEPTOR;

BLOOD CLOTTING; COMPLEX FORMATION; CRYSTAL STRUCTURE; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; THROMBOGENESIS; THROMBOSIS; BINDING COMPETITION; CHEMISTRY; KINETICS; METABOLISM; PHYSIOLOGY; REVIEW;

BINDING, COMPETITIVE; BLOOD COAGULATION FACTORS; FIBRIN; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; KINETICS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; SODIUM; THROMBIN; THROMBOMODULIN;

EID: 33746859068     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000228844.65168.d1     Document Type: Short Survey

References (116)

1. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310-1312.
2. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30:10363-10370.
3. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23:17-25.
4. Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ Jr, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci U S A. 1990;87:7623-7627.
5. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887.
6. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990;29:1118-1128.
7. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 2004;18:1-15.
8. Yun TH, Baglia FA, Myles T, Navaneetham D, Lopez JA, Walsh PN, Leung LL. Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem. 2003;278:48112-48119.
9. Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stablizing factor (factor XIIIa). J Lab Clin Med. 1975;85:574-597.
10. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105:1085-1093.
11. Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost. 1993;70:29-35.
12. Mann KG, Elion J, Butkowski RJ, Downing M, Nesheim ME. Prothrombin. Methods Enzymol. 1981;80(pt C):286-302.
13. Krishnaswamy S, Church WR, Nesheim ME, Mann KG. Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem. 1987;262:3291-3299.
14. Boskovic DS, Krishnaswamy S. Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites. J Biol Chem. 2000;275:38561-38570.
15. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106:2605-2612.
16. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989;8:3467-3475.
17. Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem. 1983;258:9276-9282.
18. Myles T, Le Bonniec BF, Stone SR. The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1. Eur J Biochem. 2001;268:70-77.
19. Di Cera E. Thrombin interactions. Chest. 2003;124:11S-17S.
20. Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem. 1996;271:13882-13887.
21. Myles T, Yun TH, Hall SW, Leung LL. An extensive interaction interface between thrombin and factor V is required for factor V activation. J Biol Chem. 2001;276:25143-25149.
22. Myles T, Yun TH, Leung LL. Structural requirements for the activation of human factor VIII by thrombin. Blood. 2002;100:2820-2826.
23. Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost. 2005;3:1861-1872.
24. Berndt MC, Phillips DR. Purification and preliminary physicochemical characterization of human platelet membrane glycoprotein V. J Biol Chem. 1981;256:59-65.
25. Ward CM, Andrews RK, Smith AI, Berndt MC. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry. 1996;35:4929-4938.
26. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2001;276:4692-4698.
27. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
28. Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem. 2002;277:1662-1668.
29. McGowan EB, Ding A, Detwiler TC. Correlation of thrombin-induced glycoprotein V hydrolysis and platelet activation. J Biol Chem. 1983;258:11243-11248.
30. Ramakrishnan V, DeGuzman F, Bao M, Hall SW, Leung LL, Phillips DR. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci U S A. 2001;98:1823-1828.
31. Marchese P, Murata M, Mazzucato M, Pradella P, De Marco L, Ware J, Ruggeri ZM. Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. J Biol Chem. 1995;270:9571-9578.
32. Gralnick HR, Williams S, McKeown LP, Hansmann K, Fenton JW, Krutzsch H. High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains. Proc Natl Acad Sci U S A. 1994;91:6334-6338.
33. Dong JF, Li CQ, Lopez JA. Tyrosine sulfation of the glycoprotein Ib-IX complex: identification of sulfated residues and effect on ligand binding. Biochemistry. 1994;33:13946-13953.
34. De Cristofaro R, De Candia E, Landolfi R, Rutella S, Hall SW. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry. 2001;40:13268-13273.
35. Li CQ, Vindigni A, Sadler JE, Wardell MR. Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin. J Biol Chem. 2001;276:6161-6168.
36. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
37. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991;353:674-677.
38. Dumas JJ, Kumar R, Seehra J, Somers WS, Mosyak L. Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation. Science. 2003;301:222-226.
39. Celikel R, McClintock RA, Roberts JR, Mendolicchio GL, Ware J, Varughese KI, Ruggeri ZM. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science. 2003;301:218-221.
40. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:11-30.
41. Ruf W, Bender A, Lane DA, Preissner KT, Selmayr E, Muller-Berghaus G. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization. Biochim Biophys Acta. 1988;965:169-175.
42. Weisel JW, Veklich Y, Gorkun O. The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots. J Mol Biol. 1993;232:285-297.
43. Li X, Galanakis D, Gabriel DA. Transient intermediates in the thrombin activation of fibrinogen. Evidence for only the desAA species. J Biol Chem. 1996;271:11767-11771.
44. Mosesson MW. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coagul Fibrinolysis. 1997;8:257-267.
45. Lorand L, Konishi K. Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys. 1964;105:58-67.
46. Becker DL, Fredenburgh JC, Stafford AR, Weitz JI. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem. 1999;274:6226-6233.
47. Janus TJ, Lewis SD, Lorand L, Shafer JA. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry. 1983;22:6269-6272.
48. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev. 1993;7:229-242.
49. Nielsen VG, Gurley WQ Jr, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg. 2004;99:120-123.
50. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem. 1996;271:23121-23125.
51. Binnie CG, Lord ST. The fibrinogen sequences that interact with thrombin. Blood. 1993;81:3186-3192.
52. Hogg PJ, Bock PE. Modulation of thrombin and heparin activities by fibrin. Thromb Haemost. 1997;77:424-433.
53. Rose T, Di Cera E. Three-dimensional modeling of thrombin-fibrinogen interaction. J Biol Chem. 2002;277:18875-18880.
54. Yang Z, Kollman JM, Pandi L, Doolittle RF. Crystal structure of native chicken fibrinogen at 2.7 A resolution. Biochemistry. 2001;40:12515-12523.
55. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS. Functional mapping of the surface residues of human thrombin. J Biol Chem. 1995;270:16854-16863.
56. Hall SW, Gibbs CS, Leung LL. Identification of critical residues on thrombin mediating its interaction with fibrin. Thromb Haemost. 2001;86:1466-1474.
57. Pechik I, Madrazo J, Mosesson MW, Hernandez I, Gilliland GL, Medved L. Crystal structure of the complex between thrombin and the central "E" region of fibrin. Proc Natl Acad Sci U S A. 2004;101:2718-2723.
58. Mosesson MW. Fibrinogen gamma chain functions. J Thromb Haemost. 2003;1:231-238.
59. Lovely RS, Moaddel M, Farrell DH. Fibrinogen gamma' chain binds thrombin exosite II. J Thromb Haemost. 2003;1:124-131.
60. Pospisil CH, Stafford AR, Fredenburgh JC, Weitz JI. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem. 2003;278:21584-21591.
61. Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost. 2001;85:470-474.
62. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. 1996;35:10448-10453.
63. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981;78:2249-2252.
64. Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J. 1986;237:243-251.
65. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
66. Kurosawa S, Stearns DJ, Jackson KW, Esmon CT. A 10-kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site. J Biol Chem. 1988;263:5993-5996.
67. Ye J, Liu LW, Esmon CT, Johnson AE. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J Biol Chem. 1992;267:11023-11028.
68. Nagashima M, Lundh E, Leonard JC, Morser J, Parkinson JF. Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity. J Biol Chem. 1993;268:2888-2892.
69. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem. 1992;267:6164-6170.
70. Zushi M, Gomi K, Honda G, Kondo S, Yamamoto S, Hayashi T, Suzuki K. Aspartic acid 349 in the fourth epidermal growth factor-like structure of human thrombomodulin plays a role in its Ca(2+)-mediated binding to protein C. J Biol Chem. 1991;266:19886-19889.
71. White CE, Hunter MJ, Meininger DP, White LR, Komives EA. Large-scale expression, purification and characterization of small fragments of thrombomodulin: the roles of the sixth domain and of methionine 388. Protein Eng. 1995;8:1177-1187.
72. Yang L, Rezaie AR. The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C. J Biol Chem. 2003;278:10484-10490.
73. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem. 1998;273:12135-12139.
74. Yang L, Manithody C, Walston TD, Cooper ST, Rezaie AR. Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin. J Biol Chem. 2003;278:37465-37470.
75. Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, Morser J, Light DR, Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 2000;404:518-525.
76. Myles T, Le Bonniec BF, Betz A, Stone SR. Electrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: the role of the thrombin anion-binding exosite-I. Biochemistry. 2001;40:4972-4979.
77. Ye J, Esmon NL, Esmon CT, Johnson AE. The active site of thrombin is altered upon binding to thrombomodulin. Two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J Biol Chem. 1991;266:23016-23021.
78. Ye J, Esmon CT, Johnson AE. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem. 1993;268:2373-2379.
79. Koeppe JR, Seitova A, Mather T, Komives EA. Thrombomodulin tightens the thrombin active site loops to promote protein C activation. Biochemistry. 2005;44:14784-14791.
80. Vindigni A, White CE, Komives EA, Di Cera E. Energetics of thrombin-thrombomodulin interaction. Biochemistry. 1997;36:6674-6681.
81. Yang L, Manithody C, Rezaie AR. Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. Proc Natl Acad Sci U S A. 2006;103:879-884.
82. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001;276:33293-33296.
83. Olson ST, Bjork I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost. 1994;20:373-409.
84. Huntington JA. Heparin activation of serpins. In: Garg HG, Linhardt RJ, Hales CA, eds. Chemistry and Biology of Heparin and Heparan Sulfate. Oxford: Elsevier Ltd; 2005:367-398.
85. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992;267:12528-12538.
86. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-559.
87. Pratt CW, Whinna HC, Meade JB, Treanor RE, Church FC. Physicochemical aspects of heparin cofactor II. Ann N Y Acad Sci. 1989;556:104-115.
88. Tollefsen DM. Heparin cofactor II. Adv Exp Med Biol. 1997;425:35-44.
89. Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A. 1994;91:5518-5522.
90. Gan ZR, Li Y, Chen Z, Lewis SD, Shafer JA. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J Biol Chem. 1994;269:1301-1305.
91. Tsiang M, Jain AK, Gibbs CS. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J Biol Chem. 1997;272:12024-12029.
92. Olson ST, Halvorson HR, Bjork I. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J Biol Chem. 1991;266:6342-6352.
93. Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem. 1982;257:14891-14895.
94. Verhamme IM, Bock PE, Jackson CM. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem. 2004;279:9785-9795.
95. Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci U S A. 2002;99:11079-11084.
96. O'Keeffe D, Olson ST, Gasiunas N, Gallagher J, Baglin TP, Huntington JA. The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism. J Biol Chem. 2004;279:50267-50273.
97. Carter WJ, Cama E, Huntington JA. Crystal structure of thrombin bound to heparin. J Biol Chem. 2005;280:2745-2749.
98. Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol. 2004;11:857-862.
99. Dementiev A, Petitou M, Herbert JM, Gettins PG. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat Struct Mol Biol. 2004;11:863-867.
100. Ye J, Rezaie AR, Esmon CT. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J Biol Chem. 1994;269:17965-17970.
101. Di Cera E, Guinto ER, Vindigni A, Dang QD, Ayala YM, Wuyi M, Tulinsky A. The Na+ binding site of thrombin. J Biol Chem. 1995;270:22089-22092.
102. Dang OD, Vindigni A, Di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci U S A. 1995;92:5977-5981.
103. Di Cera E, Dang QD, Ayala YM. Molecular mechanisms of thrombin function. Cell Mol Life Sci. 1997;53:701-730.
104. Dang QD, Di Cera E. Residue 225 determines the Na(+)-induced allosteric regulation of catalytic activity in serine proteases. Proc Natl Acad Sci U S A. 1996;93:10653-10656.
105. Arosio D, Ayala YM, Di Cera E. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C. Biochemistry. 2000;39:8095-8101.
106. Pineda AO, Savvides SN, Waksman G, Di Cera E. Crystal structure of the anticoagulant slow form of thrombin. J Biol Chem. 2002;277:40177-40180.
107. Huntington JA, Esmon CT. The molecular basis of thrombin allostery revealed by a 1.8 A structure of the "slow" form. Structure (Camb). 2003;11:469-479.
108. Carter WJ, Myles T, Gibbs CS, Leung LL, Huntington JA. Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. J Biol Chem. 2004;279:26387-26394.
109. Pineda AO, Chen ZW, Caccia S, Cantwell AM, Savvides SN, Waksman G, Mathews FS, Di Cera E. The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem. 2004;279:39824-39828.
110. Pineda AO, Zhang E, Guinto ER, Savvides SN, Tulinsky A, Di Cera E. Crystal structure of the thrombin mutant D221A/D222K: the Asp222: Arg187 ion-pair stabilizes the fast form. Biophys Chem. 2004;112:253-256.
111. Prasad S, Cantwell AM, Bush LA, Shih P, Xu H, Di Cera E. Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin. J Biol Chem. 2004;279:10103-10108.
112. Johnson DJ, Adams TE, Li W, Huntington JA. Crystal structure of wild-type human thrombin in the Na+-free state. Biochem J. 2005;392:21-28.
113. De Filippis V, De Dea E, Lucatello F, Frasson R. Effect of Na+ binding on the conformation, stability and molecular recognition properties of thrombin. Biochem J. 2005;390:485-492.
114. Pineda AO, Carrell CJ, Bush LA, Prasad S, Caccia S, Chen ZW, Mathews FS, Di Cera E. Molecular dissection of Na+ binding to thrombin. J Biol Chem. 2004;279:31842-31853.
115. Carrell CJ, Bush LA, Mathews FS, Di Cera E. High resolution crystal structures of free thrombin in the presence of K(+) reveal the molecular basis of monovalent cation selectivity and an inactive slow form. Biophys Chem. In press.
116. Wells CM, Di Cera E. Thrombin is a Na(+)-activated enzyme. Biochemistry. 1992;31:11721-11730.